All Boehringer Ingelheim articles
-
BusinessUS to invest $160m in cancer partnership
Funds will be backed up with $55m from 11 companies to advance new cancer treatments that harness the immune system
-
BusinessBoehringer Ingelheim sheds more jobs in the US
Over 240 staff to go as company refocuses on immuno-oncology
-
BusinessLilly to buy Boehringer’s pet vaccines
Deal strengthens Lilly’s animal medicine division following recent acquisition
-
BusinessJob cuts at Takeda, Boehringer and Arena
Hundreds of positions eliminated as companies re-evaluate R&D
-
BusinessSanofi and Boehringer agree €11bn asset swap
Deal swaps Sanofi’s animal health arm for Boehringer’s consumer healthcare business as both firms aim to boost scale
-
BusinessFemale sexual desire drug approved
Concerns raised over efficacy, side effects and use of advocacy campaigning to influence regulatory decisions
-
Business
Hikma boosts generics with Roxane buyout
Acquiring the Boehringer Ingelheim subsidiary expands Hikma’s presence in US generics market
-
-
Business
Chinese buyer resurrects US Boehringer plant
UniTao will take over manufacturing site scheduled for closure, saving over 200 jobs
-
Business
Boehringer to settle blood thinner drug suits for $650m
Company confident in drug safety but says court cases are too risky
-
-
BusinessPharma manufacturing woes dog industry
Regulators are stepping up inspections, and discovering ever more problems
-
Business
Boehringer to close manufacturing plants and cut jobs
Two US plants and a total of 640 jobs to go by the end of next year
-
Business
Drug discovery becomes Facebook game
Boehringer Ingelheim offers a first look at the beta version of Syrum